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Hemoglobin Villeparisis was found during a systematic measurement of glycated 
hemoglobin. Electrospray mass spectra of the globin indicate an apparently unchanged 
molecular weight within the error range (0.01%). The tryptic digest of the p chain shows a 
chromatographically abnormal m-9 peptide. The mass-to-charge ratio value of its [M + H]+ 
ion, as measured by liquid secondary ionization mass spectrometry, is one mass unit lower 
than that of the normal p-9. However, the electrospray mass spectrum of this peptide 
exhibits mainly a doubly charged ion, whereas the normal m-9 gives a triply charged ion. 
None of the allowed single amino acid substitutions for a l-u shift down (Glu 4 Gln, 
Asp + Asn, or Asn + Ile) can explain the suppression of one protonation site. This can be 
due only to the replacement of the internal histidine by a nonbasic residue. Thus at least tie 
amino acid exchanges occur within the same peptide: one involves the internal hi&dine, and 
the sum of the mass shifts is - 1 u. Consideration of the p-9 sequence and taking account 
for the genetic code rules, the only possibility was “His 4 Tyr ( + 26 mass shift) associated 
with “‘Asn 4 Ser ( -27 mass shift). This conclusion was consistent with the tandem mass 
spectrum of the [M + HI+ ion and was further confirmed by chemical microsequencing. 
(1 A172 Sot Mass Spectrorn 1996, 7, 163-167) 
I n the past decade, a noteworthy success of mass spectrometry in determination of protein primary structures has been its application for the character- 
ization of human hemoglobin variants [l-6]. The strat- 
egy used for their structural identification requires 
several steps, in most of which mass spectrometry may 
be utilized conveniently. The initial detection of the 
variant classically is done by electrophoresis or chro- 
matography. The second step consists in a presump- 
tive identification that requires a battery of elec- 
trophoretic and functional tests [7], and most recently 
a mass measurement of the intact protein has been 
added to these procedures [6]. When, at this point of 
the investigation, the variant remains unidentified, 
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protein chemistry methods may be used to determine 
the change in primary structure. Peptide mapping that 
uses reverse-phase high-performance liquid chro- 
matography (RP-HPLC) may reveal an abnormal pep- 
tide after enzymic digestion. Analysis of the amino 
acid composition of this peptide or mass measurement 
by electrospray or fast-atom bombardment mass spec- 
trometry (FAB-MS) may provide further information. 
Finally, the location of the amino acid exchange may 
be determined by Edman degradation and microse- 
quencing or by tandem mass spectrometry 18-101. As- 
suming that the point mutation is due to a single base 
substitution in a codon triplet of the DNA, all the 
amino acid exchange possibilities are not allowed. Ac- 
cording to the genetic code, there is a strong limitation 
in the number of possible amino acid exchanges that 
are compatible with a measured mass shift [ll, 121. 
Among the more than 650 hemoglobin variants de- 
scribed, only a few are due to mechanisms other than 
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point mutations in the coding sequence. These variants 
include fusion proteins, elongated or shortened chains, 
or subunits that have more than one ammo acid change 
[13]. For instance, 16 variants, which include the one 
described here, carry two point mutations within the 
same polypeptide chain. By using the mass spectrome- 
try strategy described in the foregoing text, it is diffi- 
cult to detect double mutations that are closely sepa- 
rated within the polypeptide chain, because the ob- 
served mass shift is the cumulative sum of the shifts 
induced by each mutation. In this article we show how 
electrospray ionization used in combination with liq- 
uid secondary ionization mass spectrometry (LSIMS) 
and tandem mass spectrometry pinpoints a change in 
the number of protonation sites. This information was 
highly useful to characterize and locate the two amino 
acid exchanges present in the same tryptic peptide of 
hemoglobin Villeparisis. 
Experimental 
Purification 
Washed red blood cells were hemolyzed with four 
volumes of water and 0.5 volumes of toluene and 
centrifuged to remove membranes. Structural studies 
were performed as previously described [14]. The ab- 
normal hemoglobin component was isolated by 
preparative isoelectric focusing on a granulated flat 
bed. Globin was deheminized by the acid acetone 
method. The polypeptide subunits were separated by 
RP-HPLC by using an Aquapore RP 300 column (25 x 
0.46 cm) (Brownlee Labs, Santa Clara, CA) eluted with 
a gradient of isopropanol in 0.2% trifluoroacetic acid 
(TFA) 1131. 
Typsin Cleavage and Analysis of the Resulting 
Pep tides 
After aminoethylation, the chains were digested with 
TICK-treated trypsin in 25-mM ammonium bicarbon- 
ate pH 8.8 by using an enzyme to substrate ratio of 
3:lOO (w/w). The tryptic peptides were separated by 
RF’-HPLC at a flow rate of 1.5 mL/min by using a 
Vydac C8 column (25 X 0.46 cm). Elution was ob- 
tained in 70 min by developing a curvilinear gradient 
from 0 to 75% acetonitrile in 0.2% TFA. Peptides were 
collected manually in Eppendorf tubes and dried un- 
der vacuurr,. The amino acid compositions of the pep- 
tides were determined after hydrochloric acid hydroly- 
sis and pre-column derivatization into phenylthiocar- 
bamyl amino acids [151. Sequencing of the abnormal 
peptides was performed by use of an Applied Biosys- 
terns (Foster City, CA) model 470A gas-phase se- 
quencer. 
Mass Spectvomet y 
Electrospray analysis was performed on a Trio 2000 
instrument (Fisons Biotech, Manchester, U.K.). The 
needle-to-skimmer voltage was set to 3 kV. The cone- 
to-skimmer potential was 50 V. Ten microliters of the 
peptides or the globin solution in a 1:l aceto- 
nitrile:water mixture that contained 2% formic acid 
were injected into the continuous flow of the same 
solvent running at 10 /*L/mm Ten-second scans at 
l-u resolution were recorded and averaged. The VG 
MaxEnt program was used to improve both the accu- 
racy of molecular weight determination and the reso- 
lution of the protein spectra. 
Liquid secondary ion mass spectroscopy was per- 
formed on an Autospec instrument (Fisons, VG Ana- 
lytical, Manchester, UK). The cesium gun worked at 30 
kV; the ion source voltage was 8 kV. Samples were 
dissolved in a few microliters of 20% aqueous acetic 
acid and 1 PL was mixed on the target with 1 FL of a 
1:l glycerol thioglycerol mixture acidified by 1 PL of 
1% trichloroacetic acid in water. Tandem mass spectra 
were measured in the constant B/E linked scan mode 
to detect decompositions that occurred in the first 
field-free region. The helium pressure in the collision 
cell was adjusted to reduce the intensity of the ion 
beam by 50% of its original value. 
Results and Discussion 
Purification of Hemoglobin Villeparisis 
Hemoglobin Villeparisis was found during a system- 
atic quantification of glycated hemoglobins (performed 
by ion exchange HPLC) in a Caucasian French patient 
without hematologic or clinical features. The elec- 
trophoretic study showed that the abnormal 
hemoglobin had a lower isoelectric point than 
hemoglobin A, but migrated very close to it in cellu- 
lose acetate at alkaline pH. Electrophoresis of the chain 
in 6-M urea under various experimental conditions 
(pH 6.0, pH 9.0 or in the presence of Triton X) sug- 
gested that a histidine was replaced by a neutral and 
more hydrophobic residue. A structural study was 
performed because the pattern of electrophoretic mo- 
bilities of this variant differed in detail from the more 
than 200 that are available in the Data Bank of the 
Hemoglobin Laboratory of Hopital Henri Mondor 
(Creteil, France). 
The tryptic digest was analyzed first by RF’-I-IPLC 
in our standard system, with a final acetonitrile con- 
centration of 30%. This procedure showed that the 
height of the peak that normally contains /3T-5 and 
/3T-9 was halved, but failed to provide evidence of any 
additional peak. This result suggested that, under these 
experimental conditions, the abnormal peptide was not 
eluted from the column. The tryptic digest was there- 
fore analyzed by using a Vydac C8 column, which 
allowed separation of large hydrophobic peptides. This 
analysis showed that the normal p-9 peptide was 
missing. In addition, a very hydrophobic abnormal 
peak, that eluted at the end of the chromatogram was 
observed (Figure 1). The structure of this peptide was 
therefore determined by mass spectrometry. 
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Figure 1. RP-HPLC elution pattern of the aminoethylated p 
chain of hemoglobin Villeparisis. Experimental conditions: 0.2-mg 
tryptic digest was applied on a Vydac C8 column (25 x 0.46 cm) 
eluted at a flow rate of 1.5 mL/min by developing in 70 min a 
curvilinear gradient from 0 to 75% acetonitrile in 0.2% TFA. 
Mass Spectronaetry 
Electrospray mass spectrometry was performed on the 
intact globin by using the MaxEnt program to increase 
the resolution of the deconvolution process. This anal- 
ysis showed that the molecular weights of the (Y and p 
chains of hemoglobin Villeparisis were 15,126.3 + 1 
and 15,865.5 f 1 u, respectively (compared with 
15,126.3 and 15,867.4 u for normal cx and p chains). 
The above-mentioned abnormal pT-9 was examined 
by LSIMS. It exhibited a [M + H]+ ion at m/z 1668.8 
f 0.2, that is, one mass unit lower than normal p-9. 
Assuming a single amino acid substitution, a l-u shift 
downward corresponded to either Glu + Gln, Asp + 
Asn, or Asn + Ile exchange. Another allowed ex- 
change was Glu + Lys, but because lysine is a cleav- 
age site for trypsin, this proposal very likely has to be 
ruled out [ill. None of these amino acid exchanges 
was consistent with the electrophoretic behavior of the 
variant. In addition, when electrospray mass spectrom- 
etry of the w-9 peptide was performed, a change in 
the number of the protonation sites was detected. The 
normal p-9 gave mainly a triply charged ion at m/z 
557.3, whereas the mutated p-9 gave a doubly 
charged ion at m/z 835.0 (Figure 2). In the normal 
m-9, the triply charged ion was due to protonation at 
the three basic sites, namely, the amino terminus, the 
lysine side chain, and the internal histidine residue. 
The only possible explanation of the suppression of 
one protonation site by mutation was to postulate that 
the internal histidine residue was replaced by a neutral 
or acidic one. 
Thus, a single amino acid exchange was not consis- 
tent with these observations, but two exchanges that 
occur on the same peptide could be present: the mea- 
sured one mass shift downward should correspond to 
the sum of two mass shifts, one of them due to an 
amino acid exchange that involves the internal histi- 
dine. Fortunately, only a few possibilities have to be 
considered because of the selection requirements of 
i7. 
835.7 *+ 
835.0 *+ 
Figure 2. Electrospray mass spectra of (a) normal fl-9 and (b) 
mutated /3T-9. 
genetic rules. Histidine can be exchanged only by Pro, 
Leu, Asn, Gln, Arg, Tyr, or Asp. An exchange of 
His -+ Arg is ruled out because it would modify the 
electrophoretic behavior of the chain and introduce a 
new cleavage site for trypsin. Table 1 shows the calcu- 
lated mass shifts for a second mutation when the other 
remaining exchange possibilities for His are consid- 
ered. Examination of Table 1 shows that the only 
possibility was His + Tyr ( + 26 mass shift) associated 
with Asn + Ser ( - 27 mass shift). The two other alter- 
natives, His 3 Asn associated with Asp + His or His 
-+ Leu associated with Asn + His, could not induce 
changes in the number of protonation sites. 
Examination of the normal pT-9 sequence revealed 
that a single Asn residue was present in this peptide. 
Thus the previously suggested double mutation is 
reasonable and the mutated m-9 peptide would be 
the result of the simultaneous exchange of the eleventh 
and the fourteenth residues, namely, His and Asn, by 
Tyr and Ser, respectively. 
This hypothesis was confirmed by interpretation of 
the collision-induced dissociation spectra of the MI-I+ 
ions of normal and abnormal peptides at m/z 1669.7 
and 1668.8, respectively (Figure 3). From the eleventh 
to the thirteenth position, the ions that contain the 
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Table 1. Amino acid exchange possibilities for a double mutation that involves the His residue 
and allows a -1-u cumulative mass shift of the ST-9 peptide (67Val-Ler~-Gly-Ala-Phe-Ser-Asp-Gly- 
Leir-Ala-nHis-Leu-Asp-BOAsn-Leu-82Lys, where the exchanged residues under consideration 
are underlined) 
Exchanges of His Calculated mass Change in the 
allowed by the Mass differencefor a Corresponding number of 
genetic code difference second exchange mutation protonable sites 
Arga +19 20 None - 
Asn 23 +22 Asp --$ His 0 
Asp 22 +21 None - 
Gln 9 +8 None - 
Leu 24 +23 Asn --) His 0 
Pro 40 +39 None 
Tvr f26 27 Asn -t Ser 1 
a Not considered; new tryptic cleavage. 
N-terminus (A,,, B,,, A,,, B,,, A,,, B,,) were shifted 
upward 26 mass units, because of the presence of Tyr 
instead of His at the eleventh residue. In contrast, the 
mass of the B,, fragment was shifted downward one 
mass unit. This locates the second amino acid ex- 
change at the fourteenth position from the N-terminus. 
Ions that contain the C-terminus were shifted down 
4 
b) 
Figure 3. Collision-induced dissociation spectra of [M + HI+ 
ions generated by IS&IS (B/E scans): (a) normal n-9 at n@ 
1669; (b) mutated pT-9 at m/z 1668. 
one mass unit from Y;6 to W, (Scheme I). The Yi ion 
also was shifted downward one mass unit. This result 
confirms that amino acid exchange occurs at the first 
six residues from the C-terminus, which agrees with 
the Asn + Ser exchange. No sequence ions from the 
carboxyl-containing series were detected to confirm 
once more the exchange of the His residue. However, 
the sequence of the modified p-T9 peptide was diffi- 
cult to deduce reliably from the tandem mass spec- 
trum alone, because of the relatively large width of the 
fragment peaks. In particular, differentiation between 
A fragments (B - 28 ions) and B ions shifted down- 
ward 27 mass units by the first mutation. 
Finally, because of its biological significance, the 
assignment of this double mutation was verified both 
by amino acid analysis and chemical microsequencing. 
Amino acid analysis of the chromatographic peak 
showed that it was indeed a p-9 peptide, but one that 
had more than one abnormality: one His and one Asn 
were missing and there was an additional Tyr and Ser. 
By microsequencing, Tyr instead of His was found at 
the eleventh position and Ser instead of Asn at the 
fourteenth position of peptide m-9. These results con- 
firm definitively the reliability of the mass spectrome- 
try determinations. 
Y”,, Y”,,Y”,, Y”,,Y”,, Y”, YWa Y”,Y”, 
1456 13991326 11611094 979 922 609 736 
10611191 1296 1410 
h 52 53 814 
Y”,,Y”,,Y”,, Y”,, Y”,,Y”, Y”,Y”,Y”, 
1467 14001329 1162 1095 960 923 610 739 
Scheme I. Sequence ions from the decomposition of protonated 
normal and abnormal /3T-9 peptides. 
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